GlassScriptPhysician profile
Lee A Campbell
NPI 1952845752
$7,950.18
in general payments reported to CMS, 2019-2025
29 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,759 · 2022: $1,601 · 2023: $1,676 · 2024: $1,571 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,590.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,233.91 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $801.82 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $704.10 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Corium, LLC | $669.79 | 2022-2025 | Azstarys |
| Lundbeck LLC | $568.79 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $468.22 | 2022-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $466.94 | 2021-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Neurocrine Biosciences, INC. | $413.61 | 2024-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $386.79 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $367.31 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $351.30 | 2022-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $327.03 | 2021-2022 | |
| Bausch Health US, LLC | $235.65 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $127.46 | 2021-2025 | Fanapt, Hetlioz |
| Jazz Pharmaceuticals INC. | $114.48 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $109.42 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $103.17 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Janssen Biotech, INC. | $79.16 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $75.74 | 2021-2023 | Belsomra |
| Tris Pharma INC | $61.48 | 2023 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $54.72 | 2024-2025 | Cobenfy |
| Eisai INC. | $36.55 | 2021 | |
| Vertical Pharmaceuticals, LLC | $36.31 | 2025 | Relexxii |
| Ironshore Pharmaceuticals INC. | $33.97 | 2022-2024 | |
| Alfasigma USA, INC. | $33.69 | 2022 | |
| Aytu Biopharma, INC. | $31.98 | 2021 | |
| Ucb, INC. | $29.91 | 2025 | Bimzelx |
| Idorsia Pharmaceuticals US INC | $14.00 | 2024 | Quviviq |
| Livanova USA, INC. | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.